Literature DB >> 26088118

Sense and Sensibility When Prescribing 'Off-Label' to Psychiatric Patients.

David S Baldwin1, Nupur Tiwari, Robert Gordon.   

Abstract

Pharmacological treatment forms part of much routine psychiatric practice. Many psychotropic drugs and psychotherapies are available for treating patients with mental disorders, but considerable numbers of individuals remain troubled by incapacitating symptoms even after a succession of evidence-based treatments. In this situation, many doctors consider prescribing a psychotropic medication outside the narrow terms of its market authorisation or 'product licence', in an attempt to optimise clinical outcomes and increase the chance of recovery. Despite expressed concerns about potential hazards and increased physician liability, many authorities agree that using a drug outside the narrow terms of its product licence can be an important part of clinical practice. This paper illustrates the nature and extent of the use of licensed drugs for unlicensed applications in psychiatric and other medical settings, indicates potential drawbacks and hazards, and makes recommendations for a suggested process when prescribing 'off-label', as an appropriate part of the overall management of individual patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26088118     DOI: 10.2174/1381612821666150619092353

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  4 in total

1.  Authors' Reply to Alain Braillon's Comment on "Proactive regional pharmacovigilance system versus national spontaneous reporting for collecting safety data on concerning off-label prescribing practices: An example with baclofen and alcohol dependence in France''.

Authors:  Marine Auffret; Julien Labreuche; Alain Duhamel; Sylvie Deheul; Olivier Cottencin; Régis Bordet; Sophie Gautier; Benjamin Rolland
Journal:  Drug Saf       Date:  2017-04       Impact factor: 5.606

2.  Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry.

Authors:  Gudrun Hefner; Jan Wolff; Sermin Toto; Pamela Reißner; Ansgar Klimke
Journal:  J Neural Transm (Vienna)       Date:  2022-09-07       Impact factor: 3.850

3.  Clinical characteristics and unlicensed applications of licensed psychotropic drugs within a regional tertiary service for patients with affective disorders.

Authors:  Nupur Tiwari; David S Baldwin
Journal:  Ther Adv Psychopharmacol       Date:  2018-10-23

4.  Off-label prescriptions in intensive care unit: the Chinese experience.

Authors:  Sai-Ping Jiang; Xing-Guo Zhang; Lin Liu; Hong-Yu Yang; Yan Lou; Jing Miao; Xiao-Yang Lu; Qing-Wei Zhao; Rong-Rong Wang
Journal:  Ther Clin Risk Manag       Date:  2018-01-31       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.